Pioneering X-ray crystallography work lead to the discovery that this mechanism of action is mimicked by the CDK4/6 inhibitor Palbociclib, which is successfully used in the clinic for certain breast cancers (120,131) (Figure 5A). Here, CDK4 is linked to breast carcinoma.